©2009 The WJG Press and Baishideng.
World J Gastroenterol. Apr 7, 2009; 15(13): 1613-1619
Published online Apr 7, 2009. doi: 10.3748/wjg.15.1613
Published online Apr 7, 2009. doi: 10.3748/wjg.15.1613
Table 3 Morbidity/complication profile of patients receiving pentoxifylline (group I) or prednisolone (group II) in the treatment of severe alcoholic hepatitis
| Complications | Duration of follow-up | |||
| 0-3 mo | 3 mo to 1 yr | |||
| Group I (n = 34) | Group II (n = 34) | Group I (n = 29) | Group II (n = 22) | |
| Nausea | 24 | 19 | 14 | 4 |
| Vomiting | 12 | 8 | 4 | 1 |
| Dyspepsia | 3 | 7 | 1 | 1 |
| GI bleed | - | 2 | 2 | 4 |
| Oral thrush | - | 6 | - | - |
| Sepsis | 2 | 2 | 3 | |
| Recurrent encephalopathy | 2 | - | 5 | - |
| Worsening ascites | - | 2 | - | 2 |
| Impaired glucose tolerance | - | 2 | - | 2 |
| Delayed wound healing | - | 2 | - | 1 |
| Deep vein thrombosis | - | 1 | - | - |
| Pancreatitis | - | 1 | - | - |
| Hepatorenal syndrome | - | 6 | - | - |
-
Citation: De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline
versus prednisolone for severe alcoholic hepatitis: A randomized controlled trial. World J Gastroenterol 2009; 15(13): 1613-1619 - URL: https://www.wjgnet.com/1007-9327/full/v15/i13/1613.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.1613